
|Articles|May 14, 2014
How BMS is Doing RBM (Risk-Based Monitoring)
Author(s)Guest Blogger
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Advertisement
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
3
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
4
FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay
5




